July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Short Term Effects of Carbidopa-Levodopa in Neovascular AMD
Author Affiliations & Notes
  • Brennan Michael Boyd
    College of Medicine, University of Arizona, Tucson, Arizona, United States
  • Timothy Fagan
    SnyderBiomedical, Tucson, Arizona, United States
  • Anna G. Figueroa
    Ophthalmology and Vision Science, University of Arizona, Tucson, Arizona, United States
  • Brian S McKay
    Ophthalmology and Vision Science, University of Arizona, Tucson, Arizona, United States
  • Robert W Snyder
    SnyderBiomedical, Tucson, Arizona, United States
  • Footnotes
    Commercial Relationships   Brennan Boyd, None; Timothy Fagan, SnyderBiomedical (I); Anna Figueroa, None; Brian McKay, SnyderBiomedical (I); Robert Snyder, SnyderBiomedical (I)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 356. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Brennan Michael Boyd, Timothy Fagan, Anna G. Figueroa, Brian S McKay, Robert W Snyder; Short Term Effects of Carbidopa-Levodopa in Neovascular AMD. Invest. Ophthalmol. Vis. Sci. 2019;60(9):356.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : A large retrospective cohort study shows that carbidopa-levodopa therapy delays the onset of AMD by 8 years. The retinal pigment epithelium responds to L-DOPA activation of GPR143 in vitro with up-regulation of pigment epithelium-derived factor and down-regulation of vascular endothelial growth factor (VEGF). This is the initial report on a prospective, proof of concept study to test our hypothesis that carbidopa-levodopa has a positive therapeutic effect on wet AMD.

Methods : We designed a clinical trial and filed an IND with the FDA for use of carbidopa-levodopa to treat wet AMD. Following informed consent, 8 patients with newly diagnosed wet AMD, naïve to anti-VEGF injections, were started on either carbidopa-levodopa 25-100 qhs or tid and followed weekly for 4 weeks. Patients included 3 males and 5 females, ages 63-87, and were all diagnosed by an Ophthalmologist within 1 week before study enrollment. Best corrected visual acuity (VA) was measured using an ETDRS protocol, and subjective vision changes were assessed using a survey. SD-OCT measurements of central retinal thickness (CRT) and retinal fluid were obtained. If at any time there was evidence of significant worsening, patients were referred for an anti-VEGF injection. Due to the small sample size and ethical issues of withholding treatment, a placebo group was not used.

Results : All 8 enrolled patients finished the trial; 1 was excluded from the analysis for requiring an anti-VEGF injection. VA improved by 2-7 letters in 4/7, was unchanged in 1 and worsened by 1 and 4 letters in 2/7. CRT decreased by 1-18 μm in 7/7. Retinal fluid decreased by 33-75% in 5/7 and was unchanged in 2/7. Subjective vision survey remained stable in 7/7. No drug-related adverse events were reported. Patient response to carbidopa-levodopa did not differ with respect to dosage, age, gender, time since diagnosis or baseline values for the variables measured.

Conclusions : Our results support our hypothesis that carbidopa-levodopa has a positive effect on wet AMD, as 5/7 patients were improved or stable with respect to VA, CRT, retinal fluid and subjective vision, whereas deterioration would be expected in patients not treated with anti-VEGF injections. These early findings warrant further investigation into the possibility of repurposing carbidopa-levodopa, an FDA approved drug, as an adjunctive treatment for wet AMD.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×